Legal Representation
Attorney
Joi A. White
USPTO Deadlines
Application History
22 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Sep 20, 2021 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Sep 20, 2021 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Feb 4, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 2, 2021 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Feb 2, 2021 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Feb 2, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 18, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jun 23, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jun 23, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jun 3, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| May 14, 2020 | ALIE | A | ASSIGNED TO LIE | Loading... |
| May 11, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 6, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 5, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 5, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Nov 8, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Nov 8, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Nov 8, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Oct 31, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 22, 2019 | MDSM | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Aug 21, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Aug 6, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
T-cell pharmaceutical products for the treatment of cancer; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of cancer; therapeutic cells, for medical use, for the treatment and prevention of cancer; therapeutic proteins and therapeutic antibodies, for medical use, for the treatment and prevention of cancer in humans; therapeutics and cellular therapies in the nature of proteins and protein complexes for the treatment of cancer; biologics, namely, proteins and protein complexes, for in-vitro diagnostic use for the treatment of cancer
Class 042
Provision of, and identification and development of, therapeutic targets, namely, proteins and protein complexes, for others for the treatment and prevention of cancer; development of therapeutics and cellular therapies, namely, pharmaceutical, biological and medical therapies for the treatment of cancer; biotechnology research, development, testing and analysis for the treatment of cancer; scientific research and development services; providing scientific information in the fields of treatment and prevention of cancer
Additional Information
Design Mark
The mark consists of a capital letter "A", adjacent to a line parallel to the right leg of the "A", with the number "2" appearing between both legs of the "A", and with the word "BIOTHERAPEUTICS" underneath, all in the color blue.
Color Claim
The color(s) blue is/are claimed as a feature of the mark.
Pseudo Mark
A TWO BIOTHERAPEUTICS
Classification
International Classes
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOTHERAPEUTICS"